Vildagliptin diabetes drug molecule

Vildagliptin diabetes drug molecule

A624/0530 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 39.2MB

Downloadable file size: 508.7KB

Price image Pricing

Please login to use the price calculator


Caption: Vildagliptin diabetes drug molecule, computer model. Vildagliptin, which is marketed as Galvus by Novartis, belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It works to reduces hyperglycemia (high blood sugar) in type II diabetes, by inhibiting the inactivation of the hormones GLP-1 and GIP. This results in the secretion of insulin (the hormone that regulates blood glucose levels) in the beta cells and the suppression of glucagon release (which leads to raised blood glucose levels) by the alpha cells of the islets of Langerhans in the pancreas. Atoms are colour-coded: carbon (yellow), hydrogen (white), nitrogen (green) and oxygen (pink).

Release details: Model release not required. Property release not required.

Keywords: (dpp-4), agent, anti-diabetic, anti-hyperglycemic, artwork, atom, atoms, biochemical, biochemistry, blood glucose level, blood sugar level, c17h25n3o2, chemical, chemistry, composition, compound, compounds, diabetes, diabetes mellitus, dipeptidyl peptidase-4, drug, galvus, illustration, inhibiting, inhibitor, inhibits, laf237, medical, medicine, molecular, molecular model, molecule, molecules, novartis, one, oral, pharmaceutical, pharmaceutics, pharmacological, pharmacology, single, space fill, space filled, space-fill, space-filled, spacefill, spacefilled, structure, type 2, type ii, vildagliptin

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.